Production (Stage)
Bolt Biotherapeutics, Inc.
BOLT
$5.94
$0.172.95%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -67.87% | -2.36% | 35.86% | 64.64% | 67.96% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -67.87% | -2.36% | 35.86% | 64.64% | 67.96% |
| Cost of Revenue | -19.74% | -8.21% | -1.57% | -5.80% | -9.94% |
| Gross Profit | 9.08% | 9.07% | 6.48% | 13.85% | 18.33% |
| SG&A Expenses | -27.72% | -18.08% | -11.33% | -1.45% | 2.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.39% | -9.69% | -3.02% | -3.59% | -5.90% |
| Operating Income | 15.51% | 10.45% | 6.63% | 9.26% | 11.77% |
| Income Before Tax | -0.51% | 8.79% | 8.71% | 13.84% | 22.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.51% | 8.79% | 8.71% | 13.84% | 22.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -0.51% | 8.79% | 8.71% | 13.84% | 22.57% |
| EBIT | 15.51% | 10.45% | 6.63% | 9.26% | 11.77% |
| EBITDA | 15.74% | 10.61% | 6.76% | 9.50% | 12.10% |
| EPS Basic | 0.40% | 9.68% | 9.64% | 14.75% | 23.40% |
| Normalized Basic EPS | 14.30% | 9.86% | 8.09% | 13.33% | 17.75% |
| EPS Diluted | 0.40% | 9.68% | 9.64% | 14.75% | 23.40% |
| Normalized Diluted EPS | 14.30% | 9.86% | 8.09% | 13.33% | 17.75% |
| Average Basic Shares Outstanding | 0.91% | 0.98% | 1.02% | 1.04% | 1.10% |
| Average Diluted Shares Outstanding | 0.91% | 0.98% | 1.02% | 1.04% | 1.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |